Cara Therapeutics has reported the successful completion of a Phase 1b trial of an intravenous formulation of its CR845 in dialysis patients.

“The completion of this Phase 1b trial and initiation of the Phase 2 study in uremic pruritus is an important step in establishing the potential clinical utility of CR845 in this area of significant unmet medical need,” said Frédérique Menzaghi, Ph.D., vice president of research and development.”We are particularly encouraged that preliminary data from this trial indicate that CR845 effectively reduced “worst itching” scores in those subjects who entered the study with ongoing moderate-to-severe uremic pruritus.”